Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Deviation from the plan, path or norms. Choosing an alternative way, changing the plans and flexibility.

Pipeline

Kiniksa Axes Sjögren’s Program, AstraZeneca-Licensed Antibody in Cardio Pivot

Kiniksa will now focus its development efforts on the IL-1 blocker KPL-387, which it is testing for recurrent pericarditis with Phase II/III trials planned for mid-2025.

February 26, 2025

2 min read

Tristan Manalac

Achieve goal concept art collage. Rising arrow chart and halftone hand pointing to center of dartboard. Business goal, achieve targets, success. Trendy modern retro vector illustration

Neuroscience

Emalex Heads to FDA After Phase III Tourette Syndrome Win

Emalex is gearing up for a New Drug Application for ecopipam in Tourette syndrome later this year.

February 26, 2025

2 min read

Tristan Manalac

Employees Walking In And Out Of The Door, Some Were Leaving Their Job And Some Were Being Hired At The Same Time. Full Length, Isolated On Solid Color Background. Vector, Illustration, Flat Design, Character.

Layoffs

Repare Therapeutics to Cut Staff Again, This Time by 75%

The latest Repare Therapeutics layoffs will include its chief medical officer and could leave the biotech with fewer than 35 employees as it works to advance two Phase I clinical programs.

February 25, 2025

2 min read

Angela Gabriel

Pictured: Facade of Takeda's office in Massachusetts

Collaboration

Takeda Pumps $770M Into Another BridGene Pact to Hit ‘Undruggable’ Targets

BridGene strikes another partnership with Takeda as the latter company continues its dealmaking streak, following high-ticket agreements with Keros Therapeutics, AC Immune and Degron Therapeutics in the past nine months.

February 25, 2025

2 min read

Tristan Manalac

Podcast

Examining Gene Therapies, Bispecific Antibodies and Other Novel Modalities

At the 2025 National Biotechnology Conference, gene therapies, bispecific antibodies and other novel modalities—relative newcomers to medicine—will be much discussed. In this curtain raiser, BioSpace speaks with conference chair Prathap Nagaraja Shastri of J&J about these highly anticipated topics.

February 25, 2025

1 min read

Jef Akst

Loss of one drug name. Ban on a drug or its shortage. Exclusion from the list of free drugs available under the medical social program.

Drug shortages

Compounders Sue FDA for Declaring Ozempic, Wegovy Shortage Over

The Outsourcing Facilities Association, a trade group representing compounders, filed a similar lawsuit in October last year after the FDA formally ended the tirzepaptide shortage.

February 25, 2025

2 min read

Tristan Manalac

Johnson & Johnson's business center in Switzerland

Legal

J&J Takes Samsung Bioepis to Court Over ‘Unlawful’ Stelara Biosimilar Sublicense

Samsung Bioepis allegedly entered into an agreement with a third-party health company, allowing it to market its own private label of a Stelara biosimilar.

February 25, 2025

2 min read

Tristan Manalac